Cargando…
KEYNOTE-407: an effective and safe first-line treatment option for metastatic squamous non-small cell lung cancer
Autores principales: | Chen, Hao, Yumoto, Kentaro, Kashizaki, Fumihiro, Koizumi, Harumi, Ikeda, Ichiro, Horita, Nobuyuki, Takahashi, Kenichi, Kaneko, Takeshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483082/ https://www.ncbi.nlm.nih.gov/pubmed/37691862 http://dx.doi.org/10.21037/tlcr-23-271 |
Ejemplares similares
-
Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous NSCLC in KEYNOTE-407
por: Cheng, Ying, et al.
Publicado: (2021) -
The Effectiveness and Safety of Long-Term Macrolide Therapy for COPD in Stable Status: A Systematic Review and Meta-Analysis
por: Nakamura, Kazunori, et al.
Publicado: (2023) -
KEYNOTE-407: new hope for the treatment of lung squamous cell carcinoma
por: Zhao, Xinmin, et al.
Publicado: (2020) -
Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous non‐small‐cell lung cancer in KEYNOTE‐407
por: Sugawara, Shunichi, et al.
Publicado: (2023) -
Keynote 407: the combination of pembrolizumab and chemotherapy cracks the shell of squamous cell lung cancer
por: Viteri, Santiago, et al.
Publicado: (2020)